Sibel Ozdemir | Pharmacology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Sibel Ozdemir — Yunus Emre State Hospital, Turkey

Sibel Ozdemir
Affiliation Yunus Emre State Hospital
Country Turkey
Scopus ID 60749146700
Subject Area Pharmacology
Event Health Scientists Awards
ORCID 0009-0003-4671-0964

Sibel Ozdemir is a researcher associated with Yunus Emre State Hospital whose recent scholarly work connects neurology with pharmacological investigation. Published studies have examined antiseizure medicines, experimental seizure models, medication combinations, and potential interactions involving clopidogrel, valproic acid, and levetiracetam. [1] [2]

Abstract

Sibel Ozdemir is a researcher affiliated with Yunus Emre State Hospital in Turkey whose documented work addresses pharmacology, neurology, and experimental seizure research. Her recent publications examine interactions between antiplatelet and antiseizure medicines and pharmacological effects in experimental models. This profile summarizes her research themes, publications, and recognition context in research.

Keywords

Epilepsy, valproic acid, levetiracetam, clopidogrel, pentylenetetrazol, freezing behavior, antiseizure medicines, anticonvulsant efficacy, experimental seizure models, behavioral effects, drug interactions, neurology, pharmacology, and clinical pharmacology. These terms reflect the themes identified in her recent research publications. [1] [2]

Introduction

Sibel Ozdemir is affiliated with the Department of Neurology at Yunus Emre State Hospital, Eskişehir, Türkiye. Her recent scholarly record includes investigations involving antiseizure medicines, drug interactions, and neurological models. These studies connect clinical neurology with pharmacological questions concerning treatment combinations and biological responses in experimental research settings. [1] [2]

Research Profile

Sibel Ozdemir’s documented research profile centers on neurology and pharmacology, with publications involving antiseizure therapy, experimental seizure models, and medication interactions. PubMed records identify her ORCID as 0009-0003-4671-0964 and associate recent work with Yunus Emre State Hospital. The available evidence supports a clinically oriented pharmacological research profile in clinical practice. [1]

Research Contributions

Sibel Ozdemir contributes to research examining pharmacological effects in neurological conditions. A 2026 study evaluated clopidogrel alongside valproic acid and levetiracetam in a pentylenetetrazol-induced seizure model, while another study examined differential effects of valproic acid and levetiracetam on freezing behavior. These studies address medication efficacy and drug interactions in pharmacology. [1] [2]

Publications

Sibel Ozdemir is listed as an author on publications concerning antiseizure pharmacology and neurological experimental models. Her 2026 International Journal of Molecular Sciences article investigated clopidogrel with valproic acid and levetiracetam, while a 2026 Journal of Biotechnology and Strategic Health Research article examined valproic acid and levetiracetam effects in rats. [1] [2]

Research Impact

Sibel Ozdemir’s research has potential relevance to pharmacological decision-making by investigating how neurological medicines behave in experimental combinations. The documented studies provide evidence about antiseizure efficacy and medication interactions, while their experimental designs also illustrate translational questions that may require further clinical investigation before broader conclusions are drawn. [1] [2]

Award Suitability

Sibel Ozdemir’s publication activity aligns with an Innovative Research Award profile through its focus on pharmacological questions in neurological research and experimental models. The publications demonstrate investigation of drug combinations and antiseizure effects. Award recognition should consider originality, methodological contribution, publication record, and relevance of the submitted research evidence overall. [1] [2]

Conclusion

Sibel Ozdemir’s available scholarly record presents a research trajectory connecting clinical neurology with pharmacology and experimental seizure research. Her recent publications provide documented evidence of work on antiseizure medicines and drug interactions. Continued publication, independent validation, and clinical translation would further clarify the broader significance of these research contributions today. [1] [2]

References

    1. Özdemir, S., Bolayır, E., & Şahin İnan, Z. D. (2026). Effects of Clopidogrel on the Anticonvulsant Efficacy of Valproic Acid and Levetiracetam in a PTZ-Induced Seizure Model. International Journal of Molecular Sciences, 27(14), 6415.
      https://doi.org/10.3390/ijms27146415
    2. Gürkan, İ. M., Demir Cevizlidere, B., Çalişkan, S., Özdemir, S., & Özdemir, H. (2026). Effects of nano-hydroxyapatite-coated PRF on gingiva-derived mesenchymal stem cells: In vitro study. International Journal of Molecular Sciences, 27(13), 5736.
      https://doi.org/10.3390/ijms27135736
    3. ORCID. (n.d.). ORCID record: Sibel Ozdemir, ORCID 0009-0003-4671-0964.
      https://orcid.org/0009-0003-4671-0964
    4. Elsevier. (n.d.). Scopus author details: Sibel Ozdemir, Author ID 60749146700. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=60749146700

Said Moshawih | Pharmacology | Best Researcher Award

Published on by Health Scientists
Said Moshawih
Affiliation Al-Ahliyya Amman University
Country Jordan
Scopus ID 57209745538
Documents 42
Citations 998
h-index
17
Subject Area Pharmacology
Event Health Scientists Awards
ORCID 0000-0003-4840-0460

Best Researcher Award

Said Moshawih is an academic researcher specializing in pharmacology, medicinal plants, natural products, phytochemistry, pharmaceutical sciences, and evidence-based herbal medicine. His research integrates laboratory investigations with systematic scientific reviews to evaluate bioactive compounds, therapeutic mechanisms, and translational healthcare applications. His scholarly publications have contributed to understanding herbal pharmacology, cardiovascular protection, antimicrobial activities, antioxidant mechanisms, and functional medicinal plants while supporting innovation in pharmaceutical research and healthcare advancement.[1]

Abstract

Said Moshawih has established an internationally recognized research portfolio in pharmacology through multidisciplinary investigations involving medicinal plants, phytochemistry, pharmaceutical sciences, cardiovascular health, antimicrobial agents, antioxidant compounds, and evidence-based herbal medicine. His publications emphasize translating traditional medicinal knowledge into scientifically validated therapeutic applications while encouraging sustainable healthcare innovation. Through collaborations, systematic reviews, experimental pharmacology, and natural product research, his work has strengthened pharmaceutical development, improved understanding of bioactive compounds, supported clinical relevance, and contributed valuable scientific evidence for advancing modern healthcare practices and future pharmacological discoveries.[2]

Keywords

Medicinal plants, Pharmacology, Phytochemistry, Herbal medicine, Natural products, Antioxidants, Cardiovascular health, Antimicrobial activity, Ethnopharmacology, Functional foods, Bioactive compounds, Pharmaceutical sciences, Toxicology, Drug discovery, Plant extracts.

Introduction

Said Moshawih investigates medicinal plants and pharmaceutical sciences by integrating pharmacological evidence with phytochemical characterization. His research supports safe therapeutic development, explores natural bioactive compounds, and promotes evidence-based herbal medicine for improving disease prevention, healthcare quality, and future pharmaceutical innovation through multidisciplinary scientific collaboration worldwide.[3]

Research Profile

Said Moshawih maintains an active international research profile with publications spanning pharmacology, medicinal chemistry, pharmaceutical technology, herbal therapeutics, and systematic scientific reviews. His collaborative investigations have generated influential literature supporting translational medicine while encouraging innovation across academic, clinical, and pharmaceutical research environments globally.[1]

Research Contributions

Said Moshawih has contributed significantly to understanding phytochemicals, herbal pharmacology, antioxidant mechanisms, cardiovascular protection, antimicrobial compounds, and pharmaceutical formulations. His research strengthens scientific validation of medicinal plants while encouraging interdisciplinary collaborations that bridge laboratory discoveries with practical healthcare applications and therapeutic innovations.[4]

Publications

Said Moshawih has authored numerous highly cited publications covering medicinal plants, coriander pharmacology, herbal cardiovascular benefits, antimicrobial phytochemicals, colorectal cancer prevention, pharmaceutical sciences, and evidence-based natural medicine. These publications demonstrate sustained scholarly productivity, interdisciplinary collaboration, and consistent contributions to international scientific literature.[2]

Research Impact

Said Moshawih’s research has influenced pharmaceutical sciences by providing comprehensive evidence supporting medicinal plants and natural therapeutics. His publications receive substantial academic recognition through citations, demonstrating meaningful impact on pharmacological research, healthcare innovation, systematic reviews, and future evidence-based therapeutic development internationally.[1]

Award Suitability

Said Moshawih demonstrates strong qualifications for the Best Researcher Award through impactful publications, substantial citation performance, international collaborations, and continuous advancement of pharmacological knowledge. His scientific achievements reflect excellence in research quality, innovation, scholarly influence, and contributions benefiting healthcare and pharmaceutical sciences.[1]

Conclusion

Said Moshawih continues advancing pharmacology through innovative investigations involving medicinal plants, pharmaceutical sciences, and natural products. His sustained scholarly productivity, collaborative research, and evidence-based scientific contributions reinforce his reputation as a respected researcher supporting future developments in healthcare, therapeutic innovation, and pharmaceutical research worldwide.[2]

References

  1. Elsevier. (n.d.). Scopus Author Details: Said Moshawih, Author ID 57209745538. Scopus.
    https://www.scopus.com/pages/authors/57209745538
  2. ResearchGate. (n.d.). Research Profile of Said Moshawih.
    https://www.researchgate.net/profile/Said-Moshawih
  3. ORCID. Said Moshawih Research Profile.
    https://orcid.org/0000-0003-4840-0460
  4. Google Scholar. Said Moshawih Citation Profile.
    https://scholar.google.com/citations?user=_eqg7H4AAAAJ&hl=en&oi=ao
  5. Al-Ahliyya Amman University. Faculty Profile: Said Moshawih.
    https://www.ammanu.edu.jo/staff-directory/faculty-of-pharmacy/said-moshawih/

Raphael Duval | Pharmacology | Research Excellence Award

Published on by Health Scientists

Prof. Dr. Raphael Duval | Pharmacology | Research Excellence Award

Dean | Université de Lorraine | France

Raphaël E. Duval is a senior academic leader and clinical microbiologist serving as Professor and Dean of the Faculty of Pharmacy at Université de Lorraine, France. His expertise spans infectiology, virology, cellular biology, and pharmaceutical sciences, with a strong focus on the discovery and development of innovative anti-infective and anticancer therapeutic agents. His research is widely disseminated through international peer-reviewed journals, scholarly book chapters, patents, and invited scientific communications, reflecting significant academic influence and citation impact. He actively collaborates with multidisciplinary teams across academia and industry at national and international levels. Recognized through prestigious scientific awards and fellowships, his work contributes to advancing therapeutic innovation, strengthening infectious disease management, and addressing major public health challenges with meaningful societal and clinical impact. He has 4909 citations from 98 documents with an h-index of 34.

Citation Metrics (Scopus)

4909
3500
2000
1000
0

Citations

4,909

Documents

98

h-index

34

Citations

Documents

h-index

View Google Scholar Profile
 View Scopus Profile
 View Orcid Profile

Featured Publications

Sina Andalib | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Sina Andalib | Pharmacology | Best Researcher Award

correspond author | Zanjan university of medical sciences | Iran

Dr. Sina Andalib is an Associate Professor at the Department of Pharmacology, Pharmacy Faculty, Zanjan University of Medical Sciences, Iran. He earned his Doctor of Veterinary Medicine (DVM) from Tabriz Azad University in 2005, focusing on anti-inflammatory effects of statins, and completed his PhD at Tabriz University of Medical Sciences in 2013, investigating the cardioprotective effects of Atorvastatin in isoproterenol-induced heart failure in rats. Dr. Andalib’s research spans pharmacology, neurodegenerative diseases, drug delivery systems, and natural product therapeutics, with a particular focus on Alzheimer’s disease, Parkinson’s disease, diabetes, and cancer. He has supervised numerous PhD and PharmD theses exploring innovative nanoparticle-based drug delivery, herbal and synthetic compound interventions, and molecular mechanisms underlying neuroprotection and cardioprotection. His work has been published extensively in high-impact international journals including ACS Chemical Neuroscience, Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, and European Journal of Pharmacology, covering topics such as nanocomposite hydrogels for wound healing, fullerene-based interventions in Alzheimer’s models, and polypharmacological effects of anticancer compounds. Dr. Andalib has contributed to several internationally collaborative projects, including the development of nanocomposites for neuroprotection and polypharmacological studies of anticancer compounds in organoid models. He has received recognition for his scientific contributions in pharmacology and neurotherapeutics and serves on editorial boards of peer-reviewed journals in pharmacology and drug delivery research. In addition to his research, he holds leadership roles at Zanjan University, including Head of the Department of Pharmacology and Toxicology and Head of the Education Development Office, fostering academic development and innovative research in pharmaceutical sciences. He has 751 citations from 39 documents with an h-index of 15.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Danafar, H., Sharafi, A., Kheiri Manjili, H., & Andalib, S. (2017). Sulforaphane delivery using mPEG–PCL co-polymer nanoparticles to breast cancer cells.

2. Garjani, A., Fathiazad, F., Zakheri, A., Akbari, N. A., Azarmie, Y., Fakhrjoo, A., et al. (2009). The effect of total extract of Securigera securidaca L. seeds on serum lipid profiles, antioxidant status, and vascular function in hypercholesterolemic rats.

3. Barzegar-Jalali, M., Alaei-Beirami, M., Javadzadeh, Y., Mohammadi, G., et al. (2012). Comparison of physicochemical characteristics and drug release of diclofenac sodium–eudragit® RS100 nanoparticles and solid dispersions.

4. Garjani, A., Andalib, S., Biabani, S., Soraya, H., Doustar, Y., & Garjani, A., et al. (2011). Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.

5. Abedimanesh, N., Asghari, S., Mohammadnejad, K., Daneshvar, Z., et al. (2021). The anti-diabetic effects of betanin in streptozotocin-induced diabetic rats through modulating AMPK/SIRT1/NF-κB signaling pathway.